Healthcare policy nonprofit ADAP Advocacy has named William Sarraille as Special Counsel for 340B Drug Pricing Program issues, signaling a strategic effort to reform how hospitals and healthcare systems utilize drug pricing programs.
Sarraille, a renowned healthcare policy expert, will advise the organization's 340B Patient Advisory Committee on legislative, regulatory, and policy matters. His extensive background in healthcare regulations, including Medicare, Medicaid, and pharmaceutical pricing, positions him to provide critical insights into program improvements.
ADAP Advocacy CEO Brandon M. Macsata emphasized Sarraille's deep understanding of the program's original legislative intent. The organization is particularly concerned that the current implementation of the 340B program does not effectively serve underserved patients, despite hospitals maintaining substantial financial resources.
The appointment highlights growing scrutiny of the 340B Drug Pricing Program, which was originally designed to help vulnerable patient populations access affordable medications. Sarraille's expertise suggests a potential pathway to realigning the program with its core mission of supporting patients with limited healthcare access.
With Sarraille's specialized knowledge in healthcare policy, pharmaceutical pricing, and regulatory compliance, ADAP Advocacy aims to drive meaningful reform that prioritizes patient needs and the program's foundational objectives.
